CADTH | Search

Current Filters

Showing 11 - 20 results of 3551

CADTH Pharmaceutical Reviews Update — Issue 14 () (Last Updated: Mar 4, 2020)

CADTH Program Updates Pending Consultation on Aligned CADTH Review Procedures In Spring 2020, CADTH will be consulting stakeholders on its aligned procedures for its drug reimbursement reviews. The...
Project Line:
Reimbursement Review

dapagliflozin (Forxiga ) (Last Updated: Nov 10, 2021)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Forxiga
Manufacturer:
AstraZeneca Canada Inc.
Submission Type:
Initial
Indications:

​Forxiga is indicated in adults, as an adjunct to standard of care therapy, for the treatment of heart failure with reduced ejection fraction (HFrEF) to reduce the risk of CV death, hospitalization for heart failure and urgent heart failure visit, and to improve heart failure symptoms.

fremanezumab (Ajovy) (Last Updated: Mar 29, 2021)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Ajovy
Manufacturer:
Teva Canada Innovation
Submission Type:
Initial
Indications:

​Indicated for the prevention of migraine in adults who have at least 4 migraine days per month.

Download results as CSV